SCHEMBL4128941

SCHEMBL4128941

COc1cc(C=C2SC(Nc3ccc(CC(=O)O)cc3)=NC2=O)cc(-c2ccccc2)c1OC(C)C

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.42
ALDH1A1 P00352 7/20 0.42
KMT2A Q03164 6/20 0.42
MEN1 O00255 5/20 0.42
ALOX5 P09917 4/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
KDM4E B2RXH2 2/20 0.42
GAA P10253 1/20 0.42
NR1H4 Q96RI1 2/20 0.40
S1PR1 P21453 1/20 0.40
HPGD P15428 4/20 0.39
THRB P10828 1/20 0.38
LMNA P02545 3/20 0.36
NPSR1 Q6W5P4 2/20 0.36
PSMD14 O00487 1/20 0.36
MMP2 P08253 1/20 0.36
G6PD P11413 1/20 0.36
GRIN1 Q05586 1/20 0.36
GRIN2B Q13224 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4128939 1.00 MAPT (0.42) MAPTALDH1A1KMT2AMEN1ALOX5
SCHEMBL4281386 0.87 EGFR (0.40) MAPTALDH1A1KMT2AMEN1ALOX5
SCHEMBL4281388 0.87 EGFR (0.40) MAPTALDH1A1KMT2AMEN1ALOX5
SCHEMBL4127737 0.85 KMT2A (0.49) MAPTALDH1A1KMT2AMEN1ALOX5
SCHEMBL4127729 0.85 KMT2A (0.49) MAPTALDH1A1KMT2AMEN1ALOX5
SCHEMBL4136345 0.82 KMT2A (0.51) MAPTALDH1A1KMT2AMEN1ALOX5
SCHEMBL4131441 0.82 KMT2A (0.51) MAPTALDH1A1KMT2AMEN1ALOX5
SCHEMBL4128924 0.77 S1PR1 (0.43) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL4128926 0.77 S1PR1 (0.43) MAPTALDH1A1KMT2AMEN1KDM4E
SCHEMBL4120834 0.77 S1PR1 (0.41) ALOX5S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US claimed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP claimed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO claimed
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors TORRENT PHARMACEUTICALS LIMITED (IN) 2009-04-02 US disclosed
EP-1934192-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS Torrent Pharmaceuticals Ltd (IN) 2008-06-25 EP disclosed
WO-2007032028-A1 THIAZOLINONES AND OXAZOLINONES AND THEIR USE AS PTP1B INHIBITORS TORRENT PHARMACEUTICALS LTD. (IN) 2007-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088432-A1 Thiazolinones and Oxazolinones and their Use as Ptp1b Inhibitors PTPRF, PTPA, PTPRJ MAPT 3532/4885ALDH1A1 216/4885KMT2A 2895/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.